The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Marie-Anne Goyette, Stéphanie Duhamel, Léo Aubert, Ariane Pelletier, Paul Savage, Marie‐Pier Thibault, Radia Marie Johnson, Peter Carmeliet, Mark Basik, Louis Gaboury, William J. Muller, Morag Park, Philippe P. Roux, Jean‐Philippe Gratton, Jean‐François Côté
Abstract
(Cell Reports 23, 1476–1490; May 1, 2018) The version of this paper that was originally published on May 1, 2018 contained an error in Figure 7. The image selected for the panel “Trastuzumab” in Figure 7A was not the correct one; by mistake, a cropped version of the panel “R428+Lapatinib” was used. Due to the age of the article, the paper could not be updated, but the corrected figure with a representative image of the “Trastuzumab” condition can be seen below. This change does not affect the conclusions of the experiment and the study. The authors regret this error. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer ProgressionGoyette et al.Cell ReportsMay 01, 2018In BriefMetastasis is responsible for the majority of breast cancer deaths. Goyette et al. report that AXL is expressed in HER2+ human tumors that acquire aggressive features. Blockade of AXL in mice decreases metastasis. These results suggest that co-targeting AXL and HER2 may limit the metastatic progression of HER2+ breast cancer. Full-Text PDF Open Access